Stock 002294 SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Shenzhen Salubris Pharmaceuticals Co., Ltd.

Equities

002294

CNE100000FW8

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
31.26 CNY +1.13% Intraday chart for Shenzhen Salubris Pharmaceuticals Co., Ltd. +8.50% -4.29%
Apr. 23 Salubris Pharmaceuticals' Q1 Profit Falls 5% Despite 23% Rise in Operating Income MT
Apr. 23 Salubris Pharmaceuticals to Raise Capital of US Unit by $35 Million MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Salubris Pharmaceuticals' Q1 Profit Falls 5% Despite 23% Rise in Operating Income
MT
Salubris Pharmaceuticals to Raise Capital of US Unit by $35 Million
MT
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Shenzhen Xintai Pharmaceutical's Drug to Treat Chronic Heart Failure Set for Clinical Trials
MT
Salubris Pharma's Profit, Revenue Slip in 2023
MT
Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for the Year 2023
CI
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Salubris Pharmaceuticals Gets Nod to Trial SAL0120 Tablets
MT
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Salubris Pharmaceuticals Gets US FDA Nod for Arthritis Drug Trial
MT
Precision Scientific announced that it has received funding from Shenzhen Salubris Pharmaceuticals Co., Ltd.
CI
Salubris Pharma Gets Nod for Kidney Disease Tablets
MT
Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Final Cash Dividend for A Shares for the Year 2022
CI
Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Final Cash Dividend for 2022
CI
Salubris Pharmaceuticals' 2022 Adjusted Profit Down 11%
MT
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes Final Dividend for the Year 2022
CI
Salubris Pharmaceuticals Plans to Spin Off Medical Instrument Unit for Listing
CI
Shenzhen Salubris Pharmaceuticals Co., Ltd. agreed to Spin-Off Medical Instrument Unit of Shenzhen Salubris Pharmaceuticals Co Ltd.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002294 Stock
  4. News Shenzhen Salubris Pharmaceuticals Co., Ltd.